vs
KEMPER Corp（KMPR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
KEMPER Corp的季度营收约是Revvity的1.5倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs -0.7%，领先13.4%），Revvity同比增速更快（5.9% vs -4.7%），KEMPER Corp自由现金流更多（$166.2M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -0.5%）
坎伯公司（Kemper Corporation）是总部位于美国伊利诺伊州芝加哥的保险服务商，总资产近130亿美元，旗下品牌矩阵为个人、家庭及企业客户提供多元保险产品服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
KMPR vs RVTY — 直观对比
营收规模更大
KMPR
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出10.5%
-4.7%
净利率更高
RVTY
高出13.4%
-0.7%
自由现金流更多
KMPR
多$4.4M
$161.8M
两年增速更快
RVTY
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $-8.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | -0.7% | 12.7% |
| 营收同比 | -4.7% | 5.9% |
| 净利润同比 | -108.2% | 3.9% |
| 每股收益（稀释后） | $-0.03 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KMPRRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $1.1B | $649.9M |
净利润KMPRRVTY
| Q4 25 | $-8.0M | $98.4M | ||
| Q3 25 | $-21.0M | $46.7M | ||
| Q2 25 | $72.6M | $53.9M | ||
| Q1 25 | $99.7M | $42.2M | ||
| Q4 24 | $97.4M | $94.6M | ||
| Q3 24 | $73.7M | $94.4M | ||
| Q2 24 | $75.4M | $55.4M | ||
| Q1 24 | $71.3M | $26.0M |
毛利率KMPRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率KMPRRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 11.2% | 14.3% | ||
| Q2 24 | 10.1% | 12.4% | ||
| Q1 24 | 7.6% | 6.8% |
净利率KMPRRVTY
| Q4 25 | -0.7% | 12.7% | ||
| Q3 25 | -1.7% | 6.7% | ||
| Q2 25 | 5.9% | 7.5% | ||
| Q1 25 | 8.4% | 6.4% | ||
| Q4 24 | 8.2% | 13.0% | ||
| Q3 24 | 6.3% | 13.8% | ||
| Q2 24 | 6.7% | 8.0% | ||
| Q1 24 | 6.2% | 4.0% |
每股收益（稀释后）KMPRRVTY
| Q4 25 | $-0.03 | $0.86 | ||
| Q3 25 | $-0.34 | $0.40 | ||
| Q2 25 | $1.12 | $0.46 | ||
| Q1 25 | $1.54 | $0.35 | ||
| Q4 24 | $1.51 | $0.77 | ||
| Q3 24 | $1.14 | $0.77 | ||
| Q2 24 | $1.16 | $0.45 | ||
| Q1 24 | $1.10 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $943.5M | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $12.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资KMPRRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $371.2M | $931.4M | ||
| Q2 25 | $407.6M | $991.8M | ||
| Q1 25 | $545.3M | $1.1B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $696.9M | $1.2B | ||
| Q2 24 | $539.1M | $2.0B | ||
| Q1 24 | $520.7M | $1.7B |
总债务KMPRRVTY
| Q4 25 | $943.5M | — | ||
| Q3 25 | $943.1M | — | ||
| Q2 25 | $942.6M | — | ||
| Q1 25 | $942.1M | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益KMPRRVTY
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | $2.7B | $7.4B | ||
| Q2 25 | $370.0M | $7.6B | ||
| Q1 25 | $366.0M | $7.6B | ||
| Q4 24 | $2.8B | $7.7B | ||
| Q3 24 | $2.8B | $7.9B | ||
| Q2 24 | $358.0M | $7.9B | ||
| Q1 24 | $2.6B | $7.8B |
总资产KMPRRVTY
| Q4 25 | $12.5B | $12.2B | ||
| Q3 25 | $12.4B | $12.1B | ||
| Q2 25 | $12.6B | $12.4B | ||
| Q1 25 | $12.5B | $12.4B | ||
| Q4 24 | $12.6B | $12.4B | ||
| Q3 24 | $12.6B | $12.8B | ||
| Q2 24 | $12.6B | $13.4B | ||
| Q1 24 | $12.6B | $13.4B |
负债/权益比KMPRRVTY
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 2.55× | — | ||
| Q1 25 | 2.57× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 3.88× | — | ||
| Q1 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $166.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 14.7% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $553.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流KMPRRVTY
| Q4 25 | $175.0M | $182.0M | ||
| Q3 25 | $139.9M | $138.5M | ||
| Q2 25 | $89.6M | $134.3M | ||
| Q1 25 | $180.0M | $128.2M | ||
| Q4 24 | $175.1M | $174.2M | ||
| Q3 24 | $141.9M | $147.9M | ||
| Q2 24 | $22.9M | $158.6M | ||
| Q1 24 | $43.0M | $147.6M |
自由现金流KMPRRVTY
| Q4 25 | $166.2M | $161.8M | ||
| Q3 25 | $133.4M | $120.0M | ||
| Q2 25 | $82.0M | $115.5M | ||
| Q1 25 | $172.3M | $112.2M | ||
| Q4 24 | $165.4M | $149.8M | ||
| Q3 24 | $131.4M | $125.6M | ||
| Q2 24 | $5.2M | $136.6M | ||
| Q1 24 | $27.7M | $129.7M |
自由现金流率KMPRRVTY
| Q4 25 | 14.7% | 21.0% | ||
| Q3 25 | 10.8% | 17.2% | ||
| Q2 25 | 6.7% | 16.0% | ||
| Q1 25 | 14.4% | 16.9% | ||
| Q4 24 | 13.9% | 20.5% | ||
| Q3 24 | 11.1% | 18.4% | ||
| Q2 24 | 0.5% | 19.7% | ||
| Q1 24 | 2.4% | 20.0% |
资本支出强度KMPRRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 0.5% | 2.6% | ||
| Q2 25 | 0.6% | 2.6% | ||
| Q1 25 | 0.6% | 2.4% | ||
| Q4 24 | 0.8% | 3.4% | ||
| Q3 24 | 0.9% | 3.3% | ||
| Q2 24 | 1.6% | 3.2% | ||
| Q1 24 | 1.3% | 2.7% |
现金转化率KMPRRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 1.23× | 2.49× | ||
| Q1 25 | 1.81× | 3.03× | ||
| Q4 24 | 1.80× | 1.84× | ||
| Q3 24 | 1.93× | 1.57× | ||
| Q2 24 | 0.30× | 2.87× | ||
| Q1 24 | 0.60× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KMPR
| Specialty Property Casualty Insurance Segment | $995.1M | 88% |
| Life Insurance Segment1 | $140.7M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
